After a prephase, patients with newly diagnosed ALK⁺ ALCL received 6 cycles of chemotherapy with BV. No relapses before the completion of planned therapy were observed. One occurred after completion, but before final disease reassessment. Survival was favorable and the prognostic significance of MDD was confirmed.